Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022

Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q1 2022 on May 3, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss results and provide a business update. U.S. participants can dial (855) 541-0980, while international participants can call (970) 315-0440, using Conference ID 3848138. The call will be webcast live on the company's website, with a replay available later. Veracyte specializes in diagnostic tests that enhance patient care and reduce unnecessary procedures.

Positive

• Upcoming Q1 2022 financial results announcement may show growth metrics pending expectations.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/iy7oapub. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):			(855) 541-0980
International participant dial-in number:			(970) 315-0440
Conference I.D.:			3848138

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005345/en/

Investors

Shayla Gorman - Director, Investor Relations

investors@veracyte.com

(619) 393-1545

Media

Tracy Morris - Vice President of Global Corporate Communications

tracy.morris@veracyte.com

(650) 380-4413

Source: Veracyte, Inc.

FAQ

When will Veracyte release its Q1 2022 financial results?

Veracyte will release its Q1 2022 financial results on May 3, 2022, after market close.

What time is Veracyte's conference call for Q1 2022 results?

The conference call will be held at 4:30 p.m. Eastern Time on May 3, 2022.

How can I access Veracyte's Q1 2022 conference call?

You can access the conference call via U.S. dial-in (855) 541-0980 or international dial-in (970) 315-0440, using Conference ID 3848138.

Where can I find the replay of Veracyte's conference call?

The replay of the conference call will be available on Veracyte's website following the live broadcast.

What is Veracyte's business focus?

Veracyte focuses on improving patient care through diagnostic tests that inform diagnosis and treatment decisions.